Potassium-sparing effects of triamterene in the treatment of hypertension.
D000328:Adult; D000368:Aged; D001784:Blood Gas Analysis; D001786:Blood Glucose / Q000032:analysis; D002712:Chlorides / Q000097:blood; D002740:Chlorothiazide / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood / Q000494:pharmacology*; D012964:Sodium / Q000097:blood; D014223:Triamterene / Q000009:adverse effects / Q000627:therapeutic use*; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
D001786:Blood Glucose; D002712:Chlorides; D006852:Hydrochlorothiazide; D014527:Uric Acid; D002740:Chlorothiazide; D014508:Urea; D012964:Sodium; D011188:Potassium; D014223:Triamterene